MET and ovarian carcinoma: Based on these results and others in the literature, it was suggested that the alterations of Met axis might not be attributed to a structural abnormality of c-Met, but instead it could be secondary to mutations of other genes, such as RAS (frequently mutated in ovarian cancer), that could influence the HGF/MET pathway [31, 36].